A 60 mg loading dose of the investigational antiplatelet compound prasugrel showed faster onset of activity and achieved greater inhibition of platelet aggregation than either the approved 300 mg loading dose of clopidogrel (Plavix®) or a higher 600 mg clopidogrel dose, in a Phase I study recently reported by Daiichi Sankyo (TYO: 4568) and Eli Lilly and Company (NYSE: LLY) researchers.
According to Kenneth Winters, M.D., Lilly research cardiologist:
"This data shows for the first time that as early as 30 minutes after dosing, a 60 mg prasugrel loading dose achieves greater platelet inhibition than both the approved loading dose and high-dose clopidogrel.”
Prasugrel is currently under investigation by Daiichi Sankyo and Lilly in the Phase III head-to-head clinical trial TRITON-TIMI 38, a study designed to evaluate the safety and efficacy of prasugrel versus clopidogrel in reducing ischemic events such as heart attacks, stroke and death in approximately 14,000 patients with acute coronary syndrome undergoing percutaneous coronary intervention, including coronary stenting.
The said study, expected to be completed in 2007, once successful, will be followed immediately by regulatory submissions.
Source: Eli Lilly and Co. and Daiichi Sankyo (a pdf file)
.jpg)
Comment Preview